Your browser doesn't support javascript.
loading
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).
Ricard, Fabien; Barrington, Sally; Korn, Ron; Brueggenwerth, Guenther; Trotman, Judith; Cheson, Bruce; Salles, Gilles; Schwartz, Larry; Goldmacher, Greg; Jarecha, Rudresh; Narang, Jayant; Broussais, Florence; Galette, Paul; Liu, Min; Bajpai, Surabhi; Perlman, Eric; Gillis, Julie; Smalberg, Ira; Terve, Pierre; Zahlmann, Gudrun; Schmid, Annette.
Afiliación
  • Ricard F; Relay Therapeutics, Cambridge, Massachusetts; fabienricardmd@gmail.com.
  • Barrington S; King's College London and Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom.
  • Korn R; Adjunct Faculty TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona.
  • Brueggenwerth G; Bayer AG, Berlin, Germany.
  • Trotman J; Concord Repatriation General Hospital, University of Sydney, Concord, Australia.
  • Cheson B; Lymphoma Research Foundation, New York, New York.
  • Salles G; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York.
  • Schwartz L; Department of Radiology, Columbia University College of Physicians and Surgeons and Radiologist-in-Chief, The New York Presbyterian Hospital, Columbia, New York.
  • Goldmacher G; Merck & Co, Inc., Kenilworth, New Jersey.
  • Jarecha R; Deciphera Pharmaceuticals LLC, Waltham, Massachusetts.
  • Narang J; Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts.
  • Broussais F; Lymphoma Study Association Research Center LYSARC, Pierre Benite, France Calyx International, Billerica, Massachusetts.
  • Galette P; GSK, Collegeville, Pennsylvania.
  • Liu M; Autolus Therapeutics, London, United Kingdom.
  • Bajpai S; Calyx International, Billerica, Massachusetts.
  • Perlman E; Perlman Advisory Group LLC, Boynton Beach, Florida.
  • Gillis J; Merigold LLC, Branford, Connecticut.
  • Smalberg I; Saint John's Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California.
  • Terve P; KEOSYS Medical Imaging, Saint Herblain, France; and.
  • Zahlmann G; QIBA/RSNA, Radiological Society of North America, Oak Brook, Illinois.
  • Schmid A; Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts.
J Nucl Med ; 64(2): 239-243, 2023 02.
Article en En | MEDLINE | ID: mdl-35835581
ABSTRACT
The aim of this initiative was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for the consistent application of imaging assessment with the Lugano classification.

Methods:

Consensus was obtained through a series of meetings from July 2019 to October 2021 sponsored by the PINTaD (Pharma Imaging Network for Therapeutics and Diagnostics) as part of the ProLoG (PINTaD RespOnse criteria in Lymphoma wOrking Group) consensus initiative.

Results:

Consensus recommendations encompass all technical imaging aspects of the Lugano classification. Some technical considerations for PET/CT and diagnostic CT are clarified with regards to required imaging series and scan visits, as well as acquisition and reconstruction of PET images and influence of lesion size and background activity. Recommendations are given on the role of imaging and clinical reviewers as well as on training and monitoring. Finally, an example template of an imaging case report form is provided to support efficient collection of data with Lugano Classification.

Conclusion:

Consensus recommendations are made to comprehensively address technical and imaging areas of inconsistency and ambiguity in the classification encountered by end users. Such guidance should be used to support standardized acquisition and evaluation with the Lugano 2014.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article
...